Ravi Agrawal, acting as trustee for the Ravi Agrawal Trust, has released pledge on 54,796 equity shares of Ajanta Pharma . The promoter disclosed the transaction to the Bombay Stock Exchange and the National Stock Exchange on August 14, 2026, citing "Excess Pledge" as the primary reason for the release.

The unpledging activity took place over five separate dates in early August, reducing the total encumbered stake held by the trust. As per the disclosure under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, the shares were pledged against business financing obligations.

Transaction Details

The release of encumbrance was executed across four different lenders. The transactions reduced the total pledged shares held by Ravi P. Agrwal from 1,535,096 (1.23% of total share capital) to 1,480,300 (1.18% of total share capital).

All transactions were facilitated through Barclays Securities (India) Private Limited as the depository participant.

Promoter Holding Structure

The disclosure table provides a snapshot of the broader promoter group holdings as of the reporting date. While Ravi Agrawal’s trust saw a reduction in pledged stakes, other promoters maintained their positions:

• Gabs Investments Pvt Ltd: Holds 12,588,393 shares (10.07%), with 2,770,000 shares (2.22%) remaining encumbered.
• Yogesh M Agrawal (Trustee): Holds 18,078,147 shares (14.47%) with no encumbrances.
• Rajesh M Agrawal (Trustee): Holds 18,078,148 shares (14.47%) with no encumbrances.
• Aayush M Agrawal (Trustee): Holds 14,112,924 shares (11.29%), with a significant portion of 13,532,924 shares (10.83%) still encumbered.

Ganga Exports, represented by partners Yogesh Agrawal, Rajesh Agrawal, and Ravi Agrawal, holds 3,348,261 shares (2.68%) with no pledges reported.

Ajanta Pharma Ltd has announced the schedule for its upcoming analyst and institutional investor meetings set for August 2026. The company will engage with market participants through one-on-one sessions at the Nuvama India Conference in Singapore and Hong Kong from August 11 to 13, 2026, and attend the Motilal Annual Global Conference in Mumbai on August 18, 2026. These engagements provide investors with direct access to management insights, though discussions are restricted to already published information.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that all interactions during these scheduled events will be strictly based on publicly available data, ensuring compliance with regulatory norms regarding selective disclosure.

Meeting Schedule

The detailed itinerary for the analyst and institutional investor engagements is outlined below:

Gaurang Chinubhai Shah, Senior Vice President – Legal & Company Secretary, signed the intimation on August 5, 2026. The company noted that the schedule is subject to change due to exigencies on either side. Investors are advised to monitor official communications for any updates regarding timing or venue adjustments.